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Abstract
Purpose Bone metastases secondary to solid tumors increase
the risk of skeletal-related events (SREs), including the occur-
rence of pathological fracture (PF), radiation to bone (RB),
surgery to bone (SB), and spinal cord compression (SCC).
The aim of this study was to evaluate the impact of SREs on
patients’ pain, analgesic use, and pain interference with daily
functioning.
Methods Data were combined from patients with solid tumors
and bone metastases who received denosumab or zoledronic
acid across three identically designed phase 3 trials
(N = 5543). Pain severity (worst pain) and pain interference
were assessed using the Brief Pain Inventory at baseline and
each monthly visit. Analgesic use was quantified using the
Analgesic Quantification Algorithm.
Results The proportion of patients with moderate/severe pain
and strong opioid use generally increased in the 6 months
preceding an SRE and remained elevated, while they
remained relatively consistent over time in patients without
an SRE. Regression analysis indicated that all SRE types were
significantly associated with an increased risk of progression
to moderate/severe pain and strong opioid use. PF, RB, and
SCC were associated with significantly greater risk of pain
interference overall. Results were similar for pain interference
with emotional well-being. All SRE types were associated
with significantly greater risk of pain interference with phys-
ical function.
Conclusions SREs are associated with increased pain and an-
algesic use in patients with bone metastases. Treatments that
prevent SREs may decrease pain and the need for opioid an-
algesics and reduce the impact of pain on daily functioning.
Keywords Skeletal-related events (SREs) . Denosumab .
Zoledronic acid . Pain .Brief Pain Inventory (BPI) .Analgesic
QuantificationAlgorithm (AQA)
Introduction
Bone metastases are common in patients with advanced can-
cer, particularly those with breast and prostate cancers, with
skeletal involvement in up to 75 % of patients [1, 2]. Other
solid tumors that commonly affect bone are cancers of the
lung, thyroid, kidney, and bladder [1, 2]. Advances in cancer
treatments and earlier diagnosis have extended survival; pa-
tients with breast and prostate cancers live an average of 2 to
3 years after a diagnosis of bone metastasis [3]. However,
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extending survival also prolongs the course of the disease and
its associated sequelae. Therefore, managing the symptoms of
bone metastasis has become an important goal of therapy [4].
Bone metastases disturb the natural remodeling process
between osteoblastic bone formation and osteoclastic bone
resorption. Disrupting this balance causes an increase in bone
osteolysis or in sclerotic bone depending on the lesion type
[5–7]. Metastatic bone lesions ultimately weaken the structur-
al integrity of bone, placing patients at an increased risk for
developing skeletal complications such as pain, hypercalce-
mia, or the occurrence of skeletal-related events (SREs),
which include pathological bone fractures, the need for radia-
tion to bone to manage pain and control local tumor burden,
compression of the spinal cord, and surgery to stabilize the
bone or treat an existing fracture. A total of 64 % of patients
with breast cancer and 49 % of those with prostate cancer
develop skeletal complications within 2 years if bone metas-
tases are not treated with a bone-targeted agent [8, 9], and
46 % of patients with lung cancer and other solid tumors
develop bone complications during a 21-month observation
period [10].
Pain is among the most common symptoms of bone me-
tastasis in patients with advanced disease [11, 12]. Pain has
a substantial psychological and physical impact on patients
and is one of the most feared cancer symptoms [13, 14],
with worsening pain often interpreted as disease progres-
sion [3]. The need for opioid analgesics increases as pain
worsens, but some patients are reluctant to take opioids due
to concerns about side effects (constipation, nausea, de-
creased alertness), tolerance, and addiction [3, 15]. In ad-
dition to the pain of bone metastases is the intensified pain
associated with SREs [16]. Patients who experience pain
and SREs are less able to perform daily tasks, leading to a
loss of functional independence, and treating SREs requires
travel time, work absenteeism, and possible in-patient hos-
pital stays. Therefore, treatment goals for bone metastases
include managing bone pain, delaying SREs, reducing the
incidence of multiple SREs, and preserving patients’ func-
tion and well-being [10].
Pain associated with bone metastases has been well de-
scribed [3, 12, 17], and the effects of bone-targeted agents
on pain, analgesic use, and quality of life in patients with
bone metastases have been reported previously [18, 19].
However, the precise impact of SREs exclusively, in addi-
tion to the pain of bone metastases and regardless of treat-
ment received, has not yet been defined in a large patient
population with a wide variety of tumor types. The objec-
tive of this study was to quantitate the impact of SREs by
evaluating their association with pain and analgesic use and
to determine the degree to which SREs interfere with daily
functioning in a pooled analysis of patients with bone me-
tastases who received bone-targeted agents across three
large, phase 3 clinical trials [20–22].
Methods
Study design
Data were pooled from three identically designed, internation-
al, randomized, double-blind, double-dummy, phase 3 trials
comparing denosumab and zoledronic acid in patients with
breast cancer, prostate cancer, and other solid tumors (the ma-
jority of patients in the other solid tumors trial had lung cancer
(46 %) [23, 24]). Patients with multiple myeloma enrolled in
the trial of patients with other solid tumors were excluded
from this analysis to maintain consistency with the US-
labeled indication of denosumab [25]. Eligibility criteria and
study designs from each trial and for the prespecified com-
bined analysis of these trials have been reported previously
[20–22, 26]. Briefly, patients had a primary diagnosis of breast
cancer (trial 1, N = 2046) [20], prostate cancer (trial 2,
N = 1901) [21], or other solid tumors or multiple myeloma
(trial 3, N = 1776; 180 with multiple myeloma) [22], with
radiographic evidence of at least one bone metastasis or bone
lesion and an Eastern Cooperative Oncology Group perfor-
mance status of 0, 1, or 2. Patients were excluded if they had
received prior intravenous (IV) bisphosphonate therapy and if
they had a creatinine clearance <30 mL/min (per Zometa®
prescribing information). Informed consent was obtained
from all individual participants included in the study.
Assessments
The Brief Pain Inventory Short Form (BPI-SF) was adminis-
tered to patients at baseline and each monthly visit. Pain se-
verity was based on pain at its worst, with scores ranging from
0 (no pain) to 10 (pain as bad as can be imagined). A BPI score
≤4 indicates no/mild pain, and scores >4 indicate moderate/
severe pain [12, 27, 28].
Pain interference with general activity, walking, work,
mood, enjoyment of life, relationship with others, and sleep
was also assessed using the BPI-SF. Pain interference scores
ranged from 0 (does not interfere) to 10 (completely inter-
feres). Pain interference subscales were divided according to
interference with emotional well-being or affect (relationship
with others, enjoyment of life, mood), interference with phys-
ical activity (walking, general activity, and work), and overall
interference, which includes each subscale item and sleep
[12, 27, 28]. A ≥2-point change from baseline in pain scores
is considered clinically meaningful [27].
Analgesic use was quantified at each monthly visit using
the Analgesic Quantification Algorithm (AQA). Analgesic
use was recorded as concomitant medications and converted
into AQA scores that ranged from 0 (no analgesic use) to 7
(>600 mg oral morphine equivalents per day). An AQA score
≥3 indicates strong opioid usage [29].
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The functional assessment of cancer therapy-general
(FACT-G) was completed at each monthly visit to measure
cancer-specific quality of life (QoL) [30]. FACT-G scores
are a summation of four subscale scores ranging from 0
(worst QoL) to 108 (best QoL). A ≥5-point change in the
FACT-G total score is considered clinically meaningful
[31].
Statistical analysis
All randomized patients (except patients with multiple my-
eloma) were included in this posthoc analysis. In the de-
scriptive analyses (Fig. 1), pain and analgesic use were
analyzed from 6 months before to 6 months after the index
date in both cohorts. For patients who had an on-study
SRE, the index date was the time of the first on-study
SRE. For patients who did not experience an on-study
SRE, the index date was the median time to SRE in each
SRE cohort to approximate natural disease progression.
Regression analyses were performed to assess the risk of
progressing to moderate/severe pain and strong opioid use
and the risk of clinically meaningful worsening from base-
line in pain interference associated with SREs (Fig. 2a, b,
respectively). For pain and analgesic use outcomes, hazard
ratios (HRs) and two-sided 95 % confidence intervals (CIs)
were estimated using Cox proportional hazards models
adjusting for the first on-study SRE (as time-dependent
covariate), baseline bone metastases, analgesic score at
baseline, worst pain score at baseline, region, ethnic
group/race, and gender and stratified by study, treatment,
and study randomization stratification factors. The median
time to clinically meaningful increases (≥2 points) in pain
interference from baseline was estimated using the Kaplan-
Meier method; HRs were calculated using the Cox propor-
tional hazards model. Correlations between clinically
meaningful differences in overall pain interference (≥2-
point increase) and FACT-G scores (≥5-point decrease)
were calculated based on the Mantel-Haenszel method
adjusting for study and treatment at each visit. The overall
association between pain interference and FACT-G scores
was measured based on the generalized estimating equa-
tions adjusting for study and treatment.
Results
Patients
This analysis included 5543 randomized patients from three
clinical trials. The median time on study was 12 months over-
all (17 months in the breast cancer study, 12 months in the
prostate cancer study, and 7 months in the other solid tumors
study). Baseline characteristics are shown in Table 1. Most
patients were Caucasian with a mean age of 62 years. The
most common first on-study SRE was pathological fracture,
followed by radiation to bone. A greater proportion of patients
with an on-study SRE reported moderate/severe pain (BPI >4)
at baseline compared to patients without an on-study SRE.
The mean baseline AQA scores were similar between groups
and represent nonopioid to weak opioid usage. A total of
8.4 % of patients with and 6.1 % of patients without an on-
study SRE had anAQA score ≥5 at baseline, indicating opioid
usage >300 mg oral morphine equivalent [29]. Pain interfer-
ence was similar between groups. Among individual tumor
types, patients with breast cancer and other solid tumors were
younger than patients with prostate cancer (Table 2). Radia-
tion to bone was the most common first on-study SRE in
patients with prostate cancer and other solid tumors. Patho-
logical fracture was most common in the breast cancer
population.
Burden of SREs: worst pain and analgesic use
Among patients who had an on-study SRE, the proportion of
patients with moderate/severe pain generally increased in the
6 months preceding the first on-study SRE (Fig. 1). Pain and
analgesic use were most increased after spinal cord compres-
sion. Except for surgery to bone, the proportion of patients
with moderate/severe pain remained elevated among those
with an on-study SRE compared with those without an on-
study SRE. A greater proportion of patients also progressed
from no/low analgesic use to strong opioid use after SRE
onset, with analgesic use remaining elevated for 6 months
following the SRE. Similar to the pain severity outcomes,
analgesic use remained consistent over time in those without
an SRE.
Regression analysis showed that each SRE type was sig-
nificantly associated with an increased risk of progressing
from no/mild pain to moderate/severe pain (Table 3,
Fig. 2a). Patients with spinal cord compression had the
greatest increased risk followed by patients with surgery to
bone, radiation to bone, and pathological fracture. Similarly,
each SRE type was associated with a significant risk of
progressing from no/low analgesic use to strong opioid use
(Table 3, Fig. 2a). The greatest increased risk of progressing to
strong opioid use was with spinal cord compression followed
by radiation to bone, surgery to bone, and pathological
fracture.
In the breast cancer population, those with spinal cord com-
pression had the greatest increase in risk of progressing from
no/mild pain to moderate/severe pain. However, only six pa-
tients had both spinal cord compression and a baseline pain
score ≤4 (Table 3). The risk of progressing from no/low anal-
gesic use to strong opioid use in this population was signifi-
cant for all SREs, but the greatest increase was observed with
spinal cord compression and surgery to bone. In the prostate
Support Care Cancer (2016) 24:1327–1337 1329
cancer population, patients with radiation to bone, spinal cord
compression, and pathological fracture were at a significantly
greater risk of progressing to moderate/severe pain and strong
opioid use (Table 3).
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Burden of SREs: pain interference
Patients with on-study SREs had a shorter median time to
worsening pain interference than those without on-study
SREs (Table 4). Patients with spinal cord compression, radia-
tion to bone, and pathological fracture as the first on-study
SRE were at a significantly increased risk of clinically
Fig. 1 Proportion of patients with moderate/severe pain and strong
opioid use. Moderate/severe pain is a BPI-SF worst pain score >4.
Strong opioid use is an AQA score ≥3. Study visit −6 represents the
visit 6 months before the occurrence of the first on-study SRE. The
dashed vertical line represents the occurrence of the first SRE. Study
visit 1 represents the first visit after the SRE. For patients with no SRE,
data were not consistently available for months −6, −5, and −4. AQA
Analgesic Quantification Algorithm, BPI-SF Brief Pain Inventory Short
Form, SRE skeletal-related event
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Fig. 2 a Risk of progressing to moderate/severe pain and strong opioid
use. Includes patients with baseline pain score ≤4 (pain progression;
N = 2683 or AQA score ≤2) (opioid use; N = 4340); percentages
indicate relative risk increase. *P < 005; **P < 0.01; ***P < 0.0001. b
Risk of clinically meaningful worsening (≥2-point increase) from
baseline in pain interference. Data include patients with baseline pain
interference scores ≤8; percentages indicate relative risk increase.
**P < 0.01; ***P ≤ 0.0001. AQA Analgesic Quantification Algorithm,
CI confidence interval, SRE skeletal-related event
Table 1 Population baseline and study characteristics(overall)
With on-study
SRE
N = 1925
Without on-study
SRE
N = 3618
Baseline characteristic
Female, n (%) 863 (44.8) 1733 (47.9)
Ethnic group, n (%)
White or Caucasian 1658 (86.1) 3014 (83.3)
Black or African American 61 (3.2) 102 (2.8)
Hispanic/Latino 92 (4.8) 202 (5.6)
Japanese/Asian 87 (4.5) 241 (6.7)
Othera 27 (1.4) 59 (1.6)
Age (years), mean (SD) 62.4 (11.9) 62.3 (12.3)
Tumor type, n (%)
Breast cancer 687 (35.7) 1359 (37.6)
Prostate cancer 727 (37.8) 1174 (32.4)
Other solid tumors 511 (26.5) 1085 (30.0)
Previous SREs, n (%) 867 (45.0) 1284 (35.5)
uNTX/creatinine (nmol/mmol),
mean (SD)b
87.6 (191.7) 84.4 (175.3)
BPI-SF pain severity score,
mean (SD)c
4.7 (2.9) 4.1 (2.9)
No/mild pain, n (%) 828 (43.0) 1855 (51.3)
Moderate/severe pain, n (%) 1000 (51.9) 1514 (41.8)
BPI-SF pain interference score, mean (SD)d
Overall 3.6 (2.6) 3.1 (2.7)
Emotional well-being 3.2 (2.7) 2.8 (2.7)
Physical activity 4.1 (3.0) 3.4 (3.0)
AQA score, mean (SD) 1.5 (1.8) 1.2 (1.7)
FACT-G score, mean (SD)e 71.9 (16.1) 72.6 (16.5)
On-study characteristic
First SREs, n (%)
Pathological fracture 923 (47.9) −
Radiation to bone 829 (43.1) −
Spinal cord compression 119 (6.2) −
Surgery to bone 54 (2.8) −
AQA Analgesic Quantification Algorithm, BPI-SF Brief Pain Inventory
Short Form, FACT-G functional assessment of cancer therapy-general, SD
standard deviation, SRE skeletal-related event, uNTX urinary N-
telopeptide of type 1 collagen
a BOther^ includes American Indian, Alaska Native, Native Hawaiian,
Other Pacific Islander, and others not included in these groups
b uNTX values were missing in 10.3 % of patients with on-study SREs
and 10.9 % of patients without an on-study SRE
cBPI-SF pain severity (worst pain) scores were missing in 5.0% of patients
with on-study SREs and 6.9 % of patients without an on-study SRE
d Pain interference overall scores were missing for 5.9 % of patients with
on-study SREs and 7.6 % of patients without on-study SREs. Pain inter-
ference with emotional well-being scores were missing for 7.4 % of pa-
tients with on-study SREs and 9.0 % of patients without an on-study SRE.
Pain interference with physical activity scores were missing for 8.3 % of
patients with on-study SREs and 10.1% of patients without on-study SREs
e FACT-G scores were missing for 5.2 % of patients with on-study SREs
and 7.2 % of patients without an on-study SREs
Support Care Cancer (2016) 24:1327–1337 1331
meaningful worsening in pain interference overall (Table 5,
Fig. 2b). The impact of surgery to bone was also greater,
though not significant. Results were similar for pain
interference with emotional well-being (mood, relations with
others, enjoyment of life; Table 5, Fig. 2b). All SRE types
were significantly associated with an increased risk of pain
Table 2 Population baseline and study characteristics(by tumor type)
Breast cancer Prostate cancer Other solid tumors
With on-study SRE
N = 687
Without on-study
SRE
N = 1359
With on-study
SRE
N = 727
Without on-study
SRE
N = 1174
With on-study
SRE
N = 511
Without on-study
SRE
N = 1085
Baseline characteristic
Female, n (%) 683 (99.4) 1346 (99.0) 0 (0.0) 0 (0.0) 180 (35.2) 387 (35.7)
Male, n (%) 4 (0.6) 13 (1.0) 727 (100.0) 1174 (100.0) 331 (64.8) 698 (64.3)
Age, (years), mean (SD) 56.6 (11.6) 56.7 (11.5) 69.7 (8.7) 71.5 (8.4) 59.9 (11.0) 59.6 (11.2)
BPI-SF pain severity score,
mean (SD)
4.8 (2.7) 3.9 (2.9) 4.2 (3.0) 3.7 (3.0) 5.4 (2.8) 4.9 (2.8)
No/mild pain, n (%) 292 (42.5) 750 (55.2) 369 (50.8) 676 (57.6) 167 (32.7) 429 (39.5)
Moderate/severe pain, n (%) 364 (53.0) 520 (38.3) 314 (43.2) 418 (35.6) 322 (63.0) 576 (53.1)
AQA score, mean (SD) 1.3 (1.7) 0.9 (1.4) 1.2 (1.5) 1.0 (1.4) 2.2 (2.1) 1.9 (2.0)
On-study characteristic
First SRE, n (%)
Pathological fracture 450 (65.5) – 280 (38.5) – 193 (37.8) –
Radiation to bone 201 (29.3) – 380 (52.3) – 248 (48.5) –
Surgery to bone 20 (2.9) – 5 (0.7) – 29 (5.7) –
Spinal cord compression 16 (2.3) – 62 (8.5) – 41 (8.0) –
Some (<7.5 %) BPI pain severity (worst pain) scores were missing
AQA Analgesic Quantification Algorithm, BPI-SF Brief Pain Inventory Short Form, SD standard deviation, SRE skeletal-related event
Table 3 Risk of progressing to moderate/severe pain and strong opioid use
Overalla Breast cancer Prostate cancer
HR (95 % CI) P value HR (95 % CI) P value HR (95 % CI) P value
Moderate/severe pain (patients with no/
mild pain at baseline)
N1 = 2683 N1 = 1042 N1 = 1045
PF 1.29 (1.07–1.57)
n = 418
0.0087 1.05 (0.77–1.42)
n = 197
0.7649 1.53 (1.13–2.08)
n = 149
0.0058
RB 2.51 (2.03–3.10)
n = 349
<0.0001 1.45 (0.89–2.36)
n = 84
0.1374 2.96 (2.19–3.99)
n = 187
<0.0001
SCC 3.07 (1.83–5.13)
n = 48
<0.0001 14.65 (2.32–92.47)
n = 6
0.0043 2.34 (1.19–4.60)
n = 32
0.0132
SB 2.75 (1.19–6.33)
n = 13
0.0177 1.95 (0.26, 14.54)
n = 5
0.5145 3.04 (0.42–22.25)
n = 1
0.2731
Strong opioid use (patients with no/
low analgesic use at baseline)
N2 = 4340 N2 = 1711 N2 = 1631
PF 1.72 (1.46–2.02)
n = 728
<0.0001 1.55 (1.20–1.99)
n = 362
0.0008 1.73 (1.33–2.25)
n = 238
<0.0001
RB 3.31 (2.85–3.86)
n = 609
<0.0001 2.21 (1.56–3.14)
n = 152
<0.0001 3.98 (3.24–4.90)
n = 316
<0.0001
SCC 4.81 (3.37–6.87)
n = 80
<0.0001 12.29 (4.91–30.75)
n = 12
<0.0001 4.46 (2.76–7.19)
n = 50
<0.0001
SB 2.84 (1.51–5.35)
n = 33
0.0012 5.40 (2.41–12.14)
n = 15
<0.0001 0.0 (–, –)
n = 3
0.9650
N1 number of patients with baseline BPI-SF scores ≤4,N2 number of patients with baseline AQA scores ≤2, n number of N1 orN2 patients with this type
of event as the first on-study SRE, AQA Analgesic Quantification Algorithm, BPI-SF Brief Pain Inventory Short Form, CI confidence interval, HR
hazard ratio, PF pathological fracture, RB radiation to bone, SB surgery to bone, SCC spinal cord compression, SRE skeletal-related event
a Overall population includes combined results from all three trials—breast cancer, prostate cancer, and other solid tumors
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interference with physical activity (walking, general activity,
working; Table 5, Fig. 2b).
Comparable results were observed when the effect of a first
on-study SRE on the risk of a clinically meaningful increase in
pain interference was evaluated starting at the time of SRE
diagnosis, rather than using a 28-day window.
For patients with breast cancer, spinal cord compression,
radiation to bone, and pathological fracture were significantly
associated with an increased risk of clinically meaningful
worsening in pain interference overall (Table 5). Similar re-
sults were observed in patients with prostate cancer (Table 5);
however, there were too few patients in the prostate cancer
Table 4 Kaplan-Meier estimates
of median time to a clinically
meaningful (≥2 points) increase
from baseline in pain interference
Pain interference construct Median months
for patients with
on-study SRE
Median months
for patients without
on-study SRE
Hazard ratio
(95 % CI)
P value
Overall 9.5
N1 = 1715
10.4
N2 = 3196
1.19 (1.09–1.29) <0.0001
Emotional well-being 6.9
N1 = 1687
8.4
N2 = 3132
1.16 (1.07–1.25) 0.0004
Physical activity 7.4
N1 = 1560
7.8
N2 = 2975
1.21 (1.11–1.32) <0.0001
N1 number of patients with corresponding baseline pain interference scores ≤8 who had on-study SRE, N2
number of patients with corresponding baseline pain interference scores ≤8 who did not have on-study SRE,.
CI confidence interval, SRE skeletal-related event
Table 5 Risk of clinically meaningful worsening (≥2 point increase) from baseline in pain interference
Overall population Breast cancer Prostate cancer
Hazard ratio (95 % CI) P value Hazard ratio (95 % CI) P value Hazard ratio (95 % CI) P value
Overall interference (includes sleep) N1 = 4911 N1 = 1829 N1 = 1699
PF 1.30 (1.13–1.51)
n = 822
0.0004 1.31 (1.05–1.63)
n = 403
0.0159 1.35 (1.05–1.73)
n = 246
0.0175
RB 2.29 (1.98–2.66)
n = 748
<0.0001 2.41 (1.80–3.23)
n = 183
<0.0001 2.09 (1.66–2.64)
n = 349
<0.0001
SCC 2.60 (1.84–3.68)
n = 101
<0.0001 4.26 (1.38–13.19)
n = 15
0.0120 2.36 (1.45–3.86)
n = 50
0.0006
SB 1.70 (0.97–2.98)
n = 44
0.0644 1.85 (0.68–5.05)
n = 17
0.2322 2.35 (0.32–17.04)
n = 3
0.3977
Emotional well-being N2 = 4819 N2 = 1806 N2 = 1659
PF 1.27 (1.10–1.46)
n = 802
0.0012 1.20 (0.97–1.48)
n = 399
0.1003 1.28 (1.00–1.64)
n = 239
0.0544
RB 2.44 (2.12–2.80)
n = 740
<0.0001 2.25 (1.72–2.95)
n = 183
<0.0001 2.18 (1.75–2.71)
n = 337
<0.0001
SCC 2.02 (1.41–2.91)
n = 101
0.0001 4.74 (2.15–10.44)
n = 14
0.0001 1.64 (0.93–2.89)
n = 52
0.0856
SB 1.28 (0.73–2.23)
n = 44
0.3895 1.11 (0.41–3.00)
n = 18
0.8432 1.54 (0.21–11.19)
n = 3
0.6718
Physical activity N3 = 4535 N3 = 1690 N3 = 1613
PF 1.40 (1.21–1.62)
n = 741
<0.0001 1.35 (1.09–1.69)
n = 357
0.0070 1.44 (1.12–1.84)
n = 238
0.0039
RB 2.29 (1.96–2.67)
n = 686
<0.0001 2.30 (1.70–3.10)
n = 168
<0.0001 2.09 (1.64–2.67)
n = 322
<0.0001
SCC 2.42 (1.69–3.46)
n = 95
<0.0001 2.26 (0.45–11.37)
n = 12
0.3232 1.83 (1.08–3.08)
n = 51
0.0239
SB 2.14 (1.20–3.81)
n = 38
0.0095 2.86 (1.09–7.47)
n = 15
0.0326 2.09 (0.29–15.12)
n = 3
0.4649
N1 number of patients with baseline aggregate pain interference scores ≤8; N2 number of patients with baseline pain interference affect scores ≤8; N3
number of patients with baseline pain interference activity scores ≤8; n number of N1, N2, and N3 patients with this type of event as the first on-study
SRE; CI confidence interval; PF pathological fracture, RB radiation to bone, SB surgery to bone, SCC spinal cord compression, SRE skeletal-related
event
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population with both surgery to bone and baseline pain inter-
ference scores ≤8 to provide meaningful results (n = 3).
Differences were observed in the pain interference sub-
scales for each tumor type. In patients with breast cancer,
surgery to bone, radiation to bone, and pathological fracture
were significantly associated with an increased risk of a clin-
ically meaningful increase in pain interference with physical
function. For patients with prostate cancer, the greatest risk
increase was with radiation to bone followed by spinal cord
compression. Spinal cord compression and radiation to bone
were significantly associated with an increased risk of pain
interference with emotional well-being in the breast cancer
population. For patients with prostate cancer, only radiation
to bone had a significant impact on pain interference with
emotional well-being (Table 5).
At any given study visit, up to 35 % of patients who expe-
rienced a clinically meaningful worsening in cancer-specific
QoL (≥5-point decrease) had a clinically meaningful increase
in pain interference. Significant correlations were noted be-
tween clinically meaningful increases in the overall pain in-
terference score and clinically meaningful decreases in FACT-
G total score at all visits (P < 0.0001 for all visits and overall).
Discussion
Improvements in cancer detection techniques and therapies
have extended the lives of patients, and preserving patients’
function and well-being is an important part of optimally man-
aging advanced cancer. In addition to treating bone metasta-
ses, reducing the complications of bone metastases by
delaying or preventing skeletal complications is meaningful
for patients and may lead to better overall clinical outcomes,
such as maintenance/improvement in QoL and improved sur-
vival [32–37]. Here, we have shown in a large patient popu-
lation that SREs are associated with an increase in pain and
analgesic use. These results are expected to reflect real-world
data because they are based on a large number of patients with
a variety of tumor types. Except for surgery to bone, for which
the statistical significance was limited by a small sample size,
descriptive data show that the impact is greatest around the
time of SRE occurrence, and pain and strong opioid use in
patients with an SRE generally remain elevated at least
6 months after the event compared to patients without an
SRE. These results suggest that patients who had pathological
fracture, radiation to bone, or spinal cord compression did not
fully recover following the SRE and that pain associated with
these SREs was somewhat intractable despite strong opioid
use. Managing pain associated with SREs may further expose
patients to opioid-related side effects. Patients who had sur-
gery to bone may have followed a different trend as the pro-
portion of patients with strong opioid use remained high, but
the proportion with moderate/severe pain decreased after
surgery, suggesting that patients with a need for surgery to
bone experience pain before surgery, but that the pain associ-
ated with surgery can be controlled with strong analgesic use.
However, the small sample size limits our interpretation of
these results. Patients with bone metastases who did not have
an SRE did not experience an increase in pain and analgesic
use in this study.
Among individual SREs, regression analysis showed that
spinal cord compression and radiation to bone were generally
associated with the greatest risk increase of an enduring pro-
gression in pain and analgesic use. These results were unex-
pected in patients who received radiation to bone, a palliative
treatment, and may suggest that radiation is not providing the
expected level of palliative symptom relief or that there may
be certain aspects of bone metastasis pain that are not well
controlled by radiotherapy and opioid analgesia. Indeed, pa-
tients may not respond to radiotherapy initially, or they may
have recurring pain following an initial response requiring
retreatment [38, 39]. The results could also be due to the
way we measured pain (i.e., overall pain), which accounted
for pain associated with multiple lesions that are not targeted
simultaneously by radiation.
For pathological fractures, the magnitude of the effect may
have been underestimated, because pathological fractures
were identified according to regularly scheduled skeletal sur-
veys (every 12 weeks), and may not have become symptom-
atic until later. With regard to the clinical trial design, we
chose to use regularly scheduled skeletal surveys to detect
pathological fractures objectively rather than based on
investigator/patient reports, to mitigate potential assessment
and reporting bias. While the overall burden of symptomatic
skeletal events has not been established, the treatment effect
(denosumab vs zoledronic acid) has been evaluated in patients
with prostate cancer in these trials, and the SSE and SRE
results were shown to be comparable [21, 40].
Among patients who experienced at least one SRE, 63% of
those with prostate cancer [41] and 69 % of those with breast
cancer [42] developed subsequent SREs. In our population, a
greater proportion of patients experienced an on-study SRE if
they had experienced a previous SRE, compared with patients
who did not have a previous SRE (40.3 vs 31.2%). Preventing
or delaying a first SRE would thus likely decrease the risk of
subsequent SREs.
Measuring pain severity alone is insufficient to fully cap-
ture the impact of pain on patients. Evaluating the degree to
which pain interferes with daily functioning overall as well as
with individual aspects of daily functioning (emotional well-
being and physical functioning) provides a more complete
picture of patients’ experience. In this study, all SRE types
except for surgery to bone were associated with a greater risk
of pain interference overall, which is consistent with the pain
severity results. Also, similar to the pain severity results, pa-
tients who had spinal cord compression and radiation to bone
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had the greatest risk increase in pain interference. For the
subdimensions, all SRE types except for surgery to bone had
an impact on pain interference with emotional well-being, and
all SREs, including surgery to bone, had an impact on inter-
ference with physical activity. Therefore, SREs impact not
only the sensory aspects of pain but also patients’ reaction to
pain [28]. At each study visit, there was a significant correla-
tion between increases in pain interference and decreases in
cancer-specific QoL, suggesting that preventing SREs with
bone-targeted agents may help maintain QoL in patients with
bone metastases irrespective of antitumor therapies and dis-
ease burden.
The limitations of these analyses include that they were not
prespecified. As individual SREs occur at different rates, and
as we could not control the number of events for each SRE
type, we may not have had an adequate sample size to detect
significance in some instances (e.g., surgery to bone). Addi-
tionally, in some cases, we may have underestimated the im-
pact of SREs, given that pain and analgesic use were assessed
at monthly visits rather than through diaries at the time the
SRE occurred. As such, we may not have captured the imme-
diate and likely more substantial impact of the event. The
descriptive analyses were meant to provide a visual represen-
tation of the change in pain and analgesic use over time in
patients with and without an SRE, but do not take into account
baseline differences in pain and analgesic use.We adjusted for
those baseline differences in the regression model, and pa-
tients’ onset of SRE was also factored into the time-
dependent analysis. However, considering the exploratory na-
ture of the analysis, we cannot draw conclusions about cau-
sality. Another limitation is that all patients in these studies
were receiving active treatment to delay SREs; untreated pa-
tients may have even greater increases in pain and analgesic
use as well as decreases in QoL with SRE development. A
previous report suggested that ~50 % of patients with breast
cancer and bone metastases and ~80 % of those with prostate
or lung cancer and bone metastases were not receiving treat-
ment to prevent SREs [43]. Finally, selection bias may have
caused an underestimation of the impact, because patients
with a poor performance status were excluded from the trials
and these patients may be at the highest risk for SREs and
sustained decreases in QoL related to bone complications.
Conclusion
Patients who experienced SREs were at a greater risk of in-
creased pain and opioid analgesic usage. Pain was severe
enough to interfere with daily functioning. By preventing
SREs, bone-targeted agents such as denosumab or
bisphosphonates may delay pain worsening, help patients
avoid the need for increased analgesic use, and thus reduce
the burden of SREs on daily functioning.
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